Anagram Therapeutics Funding Round

5/7/2026

Venture Equity

$250,000,000

Undisclosed

The company intends to use the funds to accelerate the development, approval and launch of its ANG003.

Private & Independent

Biopharmaceutical

33 Strathmore Rd
Natick, MA 01760
USA

Anagram Therapeutics was founded with the hope and determination to meaningfully improve the lives of people and families affected by rare and life-threatening diseases. We are developing targeted, orally delivered enzyme replacement therapies that seek to improve outcomes, reduce the high treatment burden, and deliver improved safety and tolerability. Anagram is a clinical-stage biopharmaceutical company developing novel, orally delivered enzyme therapeutics for the treatment of diseases caused by malabsorption syndromes and nutrient metabolism disorders -- enzyme deficiencies or genetic mutations that prevent the body from properly metabolizing or absorbing certain fats, sugars, proteins, vitamins, or other key nutrients. These conditions affect infants, children, and adults with congenital diseases worldwide, as well as others who might develop them as part of another illness.